FDA fast tracks former Leo Pharma eczema candidate

Union Therapeutics has been awarded fast track status by the FDA for its eczema candidate orismilast, which the biotech firm acquired from Leo Pharma.

Photo: Union Therapeutics / PR

Biotech company Union Therapeutics can take a shortcut onto the world's largest market for medical treatments, the US, after being awarded fast track status by the Food and Drug Administraion (FDA).

The special status applies to the comapny's drug candidate orismilast, which is an oral treatment for atopic dermatitis, commonly known as eczema.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs